BRENTUXIMAB VEDOTIN PLUS CHEMOTHERAPY FOR PATIENTS WITH PREVIOUSLY UNTREATED, STAGE III OR IV CLASSICAL HODGKIN LYMPHOMA: 5-YEAR UPDATE OF THE PHASE 3 ECHELON-1 STUDY (NCT01712490) Picardi, M., Straus, J., Dlugosz-Danecka, M., Connors, J. M., Illes, A., Lech-Maranda, E., Feldman, T., Smolewski, P., Savage, K. J., Bartlett, N. L., Walewski, J., Ramchandren, R., Zinzani, P. L., Hutchings, M., Munoz, J., Kim, W. S., Advani, R., Ansell, S. M., Gallamini, A., Liu, R., Little, M., Fenton, K., Fanale, M., Radford, J. FERRATA STORTI FOUNDATION. 2021: 44

View details for Web of Science ID 000719458000070